What is the purpose of the study?
We are conducting a research study to evaluate the use of esketamine for people with treatment resistant depression. The usual treatment for depression is pharmacotherapy with antidepressants such as sertraline and citalopram. However, many people do not experience sufficient improvement with these treatments. The purpose of this study is to find out the potential benefits of esketamine for treatment resistant depression. This study requires a total commitment of about 4 weeks and includes 8 clinic visits. We are located at 100 Stokes Street, M6J 1H4, Toronto, Ontario. The visits for the study will take about 2 hours.
Who is needed?
- Individuals who have been diagnosed with treatment resistant depression;
- Individuals with insurance coverage for the cost of esketamine medication OR individuals able to pay out of pocket for the medication;
- Individuals who have tried at least 2 antidepressants.
Age range: 18 -65
Study Involves Treatment? Yes
Contact Information:
E-mail: mood.research@camh.ca
Study End Date: June 6, 2026
REB number: 124/2021
Full Study Title: Efficacy and tolerability of esketamine, a novel 'standard of care' treatment, for the management of patients with treatment-resistant depression: An observational study
PLEASE NOTE:
Research staff cannot give medical advice over the phone.
If you have specific questions regarding your health care, please contact your family physician.
We regret that not everyone screened for a study will be eligible to participate
For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.